EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 3.0

Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study

Hend Ahmed El-Hadaad, Hanan Ahmed Wahba, Hayam Fathy Abd-El Hay Ghazy

Forum of Clinical Oncology · 2015

DOI: 10.1515/fco-2015-0017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Forum of Clinical Oncology, 2015. Verfasst von Hend Ahmed El-Hadaad und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Targeted agents were introduced over past years because of better understanding of oncogenetic mechanisms in metastatic renal cell carcinoma (mRCC). These agents include tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, pazopanib and axitinib.

Methods

Review of recorded data from patients’ files with mRCC were analysed during the period from August 2008 to December 2014. Those patients were treated by sunitinib as first-line therapy. The data included patients characteristics such as age, sex, ECOG performance status (ECOG PS), number and sites of metastasis and pathological type. Also, we reviewed response to sunitinib therapy, its adverse events and progression-free survival (PFS).

Results

This study included 26 patients; median age was 56 years with male predominance (76.9%) and 61.5% of patients were of ECOG PS0. Lymph nodes were the most common site of metastasis (38.5%) and 46.2% presented with ≥3 sites of disease. Clear cell pathology was reported in 96.2%. No grade IV adverse events to sunitinib reactions were observed. Thrombocytopenia was the most predominant haematological reaction (46%) followed by neutropenia (38.6%), whilst fatigue was the most reported non-haematological one (50%) followed by diarrhoea (42.3%). Partial response (PR) was found in 30.8% and stable disease (SD) in 46.2%. One-year PFS was 57.7% with median PFS time of 12 months.

Conclusion

This study proved effectiveness and safety of sunitinib as first-line treatment for mRCC. However, this is a retrospective study and relatively small numbers of patients were included, so prospective studies with larger number of patients are needed for further evaluation.

Zitieren

APA

El-Hadaad, H. A., Wahba, H. A., & Ghazy, H. F. A. H. (2015). Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study. Forum of Clinical Oncology. https://doi.org/10.1515/fco-2015-0017

Vancouver

El-Hadaad HA, Wahba HA, Ghazy HFAH. Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study. Forum of Clinical Oncology. 2015. doi:10.1515/fco-2015-0017

BibTeX
@article{ElHadaad2015,
  author = {El-Hadaad, Hend Ahmed and Wahba, Hanan Ahmed and Ghazy, Hayam Fathy Abd-El Hay},
  title = {Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study},
  journal = {Forum of Clinical Oncology},
  year = {2015},
  doi = {10.1515/fco-2015-0017}
}
Kostenlos starten →